Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C H Polman

Showing results (241-250 of 290) with videos related to

Pageof 29
Sort By:
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 27, 2010
Evaluation of the symbol digit modalities test (SDMT) and MS neuropsychological screening questionnaire (MSNQ) in natalizumab-treated MS patients over 48 weeksS A Morrow, P W O'Connor, C H Polman, et al.
Neurology|March 14, 2001
Is Epstein-Barr virus present in the CNS of patients with MS?S A Morré, J van Beek, C J De Groot, et al.
Brain : a Journal of Neurology|June 22, 2002
Markers for different glial cell responses in multiple sclerosis: clinical and pathological correlationsA Petzold, M J Eikelenboom, D Gveric, et al.
Archives of Neurology|May 13, 2009
Diffusely abnormal white matter in chronic multiple sclerosis: imaging and histopathologic analysisAlexandra Seewann, Hugo Vrenken, Paul van der Valk, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|November 13, 2013
Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFITG Edan, L Kappos, X Montalbán, et al.
Neurology|March 17, 1999
Primary and transitional progressive MS: a clinical and MRI cross-sectional studyV L Stevenson, D H Miller, M Rovaris, et al.
Neurology|May 25, 2011
No influence of KIF1B on neurodegenerative markers in multiple sclerosisM H Sombekke, N Jafari, K Bendfeldt, et al.
Annals of Neurology|June 9, 1999
Decreased interleukin-10 and increased interleukin-12p40 mRNA are associated with disease activity and characterize different disease stages in multiple sclerosisA H van Boxel-Dezaire, S C Hoff, B W van Oosten, et al.
Neurology|November 14, 2008
Sample sizes for brain atrophy outcomes in trials for secondary progressive multiple sclerosisD R Altmann, B Jasperse, F Barkhof, et al.
Neurology|August 1, 1997
Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: results of a randomized, double-blind, placebo-controlled, MR-monitored phase II trialB W van Oosten, M Lai, S Hodgkinson, et al.
Pageof 29

Showing results (241-250 of 290) with videos related to

Sort By:
Pageof 29
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 27, 2010
Evaluation of the symbol digit modalities test (SDMT) and MS neuropsychological screening questionnaire (MSNQ) in natalizumab-treated MS patients over 48 weeksS A Morrow, P W O'Connor, C H Polman, et al.
Neurology|March 14, 2001
Is Epstein-Barr virus present in the CNS of patients with MS?S A Morré, J van Beek, C J De Groot, et al.
Brain : a Journal of Neurology|June 22, 2002
Markers for different glial cell responses in multiple sclerosis: clinical and pathological correlationsA Petzold, M J Eikelenboom, D Gveric, et al.
Archives of Neurology|May 13, 2009
Diffusely abnormal white matter in chronic multiple sclerosis: imaging and histopathologic analysisAlexandra Seewann, Hugo Vrenken, Paul van der Valk, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|November 13, 2013
Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFITG Edan, L Kappos, X Montalbán, et al.
Neurology|March 17, 1999
Primary and transitional progressive MS: a clinical and MRI cross-sectional studyV L Stevenson, D H Miller, M Rovaris, et al.
Neurology|May 25, 2011
No influence of KIF1B on neurodegenerative markers in multiple sclerosisM H Sombekke, N Jafari, K Bendfeldt, et al.
Annals of Neurology|June 9, 1999
Decreased interleukin-10 and increased interleukin-12p40 mRNA are associated with disease activity and characterize different disease stages in multiple sclerosisA H van Boxel-Dezaire, S C Hoff, B W van Oosten, et al.
Neurology|November 14, 2008
Sample sizes for brain atrophy outcomes in trials for secondary progressive multiple sclerosisD R Altmann, B Jasperse, F Barkhof, et al.
Neurology|August 1, 1997
Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: results of a randomized, double-blind, placebo-controlled, MR-monitored phase II trialB W van Oosten, M Lai, S Hodgkinson, et al.
Pageof 29